Cocaine Dependence
Conditions
Brief summary
The objective of this research is to identify the functional neural mechanisms (as assessed using fMRI) of short-term N-acetylcysteine (NAC) administration among methadone-maintained individuals with cocaine dependence.
Detailed description
The objective of this research is to identify the functional neural mechanisms (as assessed using fMRI) of short-term N-acetylcysteine (NAC) administration among methadone-maintained individuals with cocaine dependence. Specifically, this application proposes to conduct a randomized, double-blind, placebo-controlled, cross-over pilot study to examine the effects of 7-day NAC administration (2400mg/day) on the neural networks engaged during response inhibition (Go/No-Go task) and affective (emotion-regulation task) processes among cocaine-dependent, methadone-maintained individuals (n=40; 20 per treatment-order condition).
Interventions
DIETARY_SUPPLEMENTN-acetylcysteine
NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
OTHERPlacebo
Sugar pill
Sponsors
National Institute on Drug Abuse (NIDA)
Yale University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. enrollment in the APT methadone program and maintained on a stable dose of methadone for ≥ 2 weeks 2. males or females, aged 18-65 3. confirmed DSM-IV diagnosis of current cocaine use disorder as assessed at the screening assessment 4. for women of a child-bearing age, acceptable birth control method 5. ability to commit to 4 weeks of study participation plus 1-month follow-up 6. willingness to be randomized to NAC or placebo 7. eligibility for MRI scanning and willingness to participate in MRI scanning.
Exclusion criteria
1. Do not meet DSM-IV criteria for cocaine-use disorder. 2. Meet DSM-IV psychiatric classifications for lifetime schizophrenia or bipolar disorder, or exhibit significant current suicidal or homicidal plans and intent such that hospitalization is required. 3. Meet DSM-IV criteria for current alcohol or other substance-use disorder dependence (with the exceptions of nicotine, cocaine and opioids). 4. Have previously taken or currently take NAC. 5. Have asthma (due to possible complications with NAC). 6. Cannot commit to 4-weeks of study participation or are unwilling to accept randomization. 7. Have any contraindications for MRI scanning (e.g., pregnancy, color-blindness, claustrophobia, metal implants that could interfere with MRI, any other contraindication to scanning). 8. Have lab work (complete blood count, urinalysis, liver function tests, thyroid function tests) suggesting the presence of any abnormalities or have a significant or unstable medical illness. 9. Are women who are pregnant or of a child-bearing age who do not agree to adequate contraception to prevent pregnancy during the study period. 10. Are not fluent in English. 11. Do not have at least a 6th grade reading level. 12. Cannot provide written, informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in neural network engagement measured using functional magnetic resonance imaging | 4 weeks | The primary outcome measure for this study is change (NAC versus placebo) in neural network engagement during fMRI task performance. |
Countries
United States
Outcome results
None listed